RETROSPECTIVE EVALUATION OF CLINICAL AND ECONOMIC OUTCOMES IN IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS TREATED WITH OR WITHOUT CAPLACIZUMAB

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/4fc69bb40a6467f44a4fca2a8824371c.pdf

Abstract Title *

RETROSPECTIVE EVALUATION OF CLINICAL AND ECONOMIC OUTCOMES IN IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS TREATED WITH OR WITHOUT CAPLACIZUMAB

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Seinosuke Horikawa seinosuke.horikawa@gmail.com Kobe City Medical Center General Hospital Nephrology Kobe Japan *

Co-author 2

Takaya Handa takaya_handa@kcho.jp Kobe City Medical Center General Hospital Nephrology Kobe Japan -

Co-author 3

Masashi Nishikubo mnishi90@yahoo.co.jp Kobe City Medical Center General Hospital Hematology Kobe Japan -

Co-author 4

Satoru Kurihara str.krhr.216@gmail.com Kobe City Medical Center General Hospital Nephrology Kobe Japan -

Co-author 5

Naoya Kamae naoya_kamae@kcho.jp Kobe City Medical Center General Hospital Clinical Engineering Kobe Japan -

Co-author 6

Fu Takata fu_shudo@kcho.jp Kobe City Medical Center General Hospital Nephrology Kobe Japan -

Co-author 7

Keisuke Osaki keisuke_osaki@kcho.jp Kobe City Medical Center General Hospital Nephrology Kobe Japan -

Co-author 8

Shusuke Hiragi glaucus.in.dusk@gmail.com Kwansei Gakuin University Institute of Business and Accounting Nishinomiya Japan -

Co-author 9

Yoshimitsu Shimomura shimomura-0119@kcho.jp Kobe City Medical Center General Hospital Hematology Kobe Japan -

Co-author 10

Ryusuke Yamamoto ryusuke_yamamoto@kcho.jp Kobe City Medical Center General Hospital Hematology Kobe Japan -

Co-author 11

Yuya Nagai yuya_nagai@kcho.jp Kobe City Medical Center General Hospital Hematology Kobe Japan -

Co-author 12

Nobuhiro Hiramoto nobuhiro_hiramoto@kcho.jp Kobe City Medical Center General Hospital Hematology Kobe Japan -

Co-author 13

Noboru Yonetani nyonetani@kcho.jp Kobe City Medical Center General Hospital Hematology Kobe Japan -

Co-author 14

Tadakazu Kondo tadakazu_kondo@kcho.jp Kobe City Medical Center General Hospital Hematology Kobe Japan -

Co-author 15

Akihiro Yoshimoto ayoshi@kcho.jp Kobe City Medical Center General Hospital Nephrology Kobe Japan -